Paddy Mallon, MD, PhD, is Professor of Microbial Diseases at UCD School of Medicine and Consultant Physician in Infectious Diseases at Mater Misericordiae University Hospital (MMUH). In 2008 he established the HIV Molecular Research Group (HMRG), the largest HIV research group in Ireland, which focuses on international, collaborative, translational research into toxicities of ART, strategies to increase population HIV testing and studies aimed at better understanding immune responses to ART. Dr Mallon is a Regional Representative for the European AIDS Clinical Society (EACS), is Deputy Chair of the EACS Comorbidities Guidelines Panel and Deputy Director of the Wellcome Trust / HRB Irish Clinical Academic Training Programme. He has published more than one hundred peer-reviewed manuscripts and sits on the editorial board of AIDS, HIV Medicine and AIDS Research and Therapy.
Eoin Feeney graduated in medicine from Trinity College Dublin in 2002. In 2012 he completed Higher Specialist Training in Infectious Diseases and General Internal Medicine through the Royal College of Physicians in Ireland, and in the same year was awarded a PhD examining the metabolic complications of HIV infection from University College Dublin. From 2012-2014 he undertook a Fellowship in Infectious Diseases at Massachusetts General Hospital and Brigham and Women’s Hospital in Boston. From 2013-2014 he was an Instructor in Medicine at Harvard Medical School. His areas of research at MGH/BWH were the mechanisms of accelerated fibrosis in HIV / hepatitis C virus co-infection. In 2014 he returned to Ireland as a Consultant Physician in Infectious Diseases and established the Infectious Diseases department at St. Vincent’s University Hospital where he is involved in the management of HIV and Hepatitis C virus infection.
Dr Aoife Cotter is Consultant in Infectious Diseases at the Mater Misericordiae and St Vincent’s University Hospitals. She completed a PhD focussing on cohort methodology and bone disease in HIV under the supervision of Dr Paddy Mallon (HMRG/ University College Dublin) and Prof Caroline Sabin (Medical Statistics and Epidemiology, University College London). In addition to HIV UPBEAT, a longitudinal cohort exploring bone health, new research interests include exploring radiological and clinical changes in those undergoing contemporary hepatitis C treatment (The TRACER Cohort) and bone, kidney and gut microbiome alterations around antiretroviral therapy initiation (The BIGGER Study). Future, projects hope to exploit contemporary mobile health technologies to assess frailty and ultimately to promote healthy ageing in people living with HIV.
Dr Gautier leads a research group focused on HIV molecular pathogenesis, the host-virus interface and HIV cure research at the UCD Centre for Research in Infectious Diseases (CRID). Dr Gautier´s group has extensive expertise in molecular and cellular virology, epigenetics, patients cell-based assays, targeted drug screening and proteomics. She has been awarded national competitive research grants from the Irish Health Research Board (HRB), the Irish Research Council (IRC) and Enterprise Ireland (EI) funding to develop her research program. In parallel, she is the coordinator of the H2020 funded European EU4HIVCURE consortium, which aims to accelerate the state of the Art in HIV CURE research in Europe.
Caroline Sabin, PhD, is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is Director of the NIHR Health Protection Research Unit in Blood-Borne and Sexually Transmitted Infections. After completing her PhD in Epidemiology, Caroline has worked on the analysis of large observational HIV databases with an interest in raising awareness of the biases inherent in these databases. Her particular interests are in describing the natural history of HIV infection, identifying prognostic markers and describing responses and adverse events to cART. She established the UK Collaborative HIV Cohort (UK CHIC) Study, a multicentre study of >50,000 HIV-positive individuals, and was the principal statistician for the D:A:D Study. More recently, together with Professor Alan Winston, she has established the POPPY Study, a cohort that aims to study the effects of ageing in HIV infection. She has been closely involved with many other large national and international HIV cohort studies.
Alison Rodger is Reader in Infectious Diseases at University College London and a Consultant in Infectious Diseases and Director of Public Health at the Royal Free Hospital in London. Alison has been a co-author of BHIVA guidelines on hepatitis co-infection, immunisations and post-exposure prophylaxis after sexual exposure (PEPSE) and co-chaired the Pre-Exposure Prophylaxis (PrEP) BHIVA guidelines (2018). She is lead author on the PARTNER HIV transmission study and is PI on the PANTHEON NIHR programme grant looking at cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among gay men. She is also developing a programme of research activities centred on meeting the challenge of morbidity and mortality from HIV and non-communicable diseases in east and southern African
Dr Jane O’Halloran graduated in Medicine from National University of Ireland, Galway and completed subsequent clinical training in infectious disease medicine in Ireland. During this time, she completed a PhD in the mechanisms contributing to increased cardiovascular disease in HIV infection. Dr O’Halloran is currently undertaking a post-doctoral fellowship at Washington University in St Louis where she continues to research in long-term co-morbidities associated with HIV infection and antiretroviral drug toxicity
Jean-michel Molina is Professor of Infectious Diseases at the University of Paris Diderot – Paris 7 (since 1997), and Head of the Infectious Diseases Department at the Saint-Louis Hospital in Paris since 2001. Professor Molina’s primary clinical research interest lies in the area of HIV infection, initially the treatment of opportunistic infections, then the treatment of HIV-infection. He has been involved in a number of studies assessing new drugs or new strategies for the treatment of HIV infection. A cohort of more than 3,500 patients with HIV-infection is followed in his department and is involved in this clinical research. He is also a member of the INSERM U941 team involved in HIV basic research the Saint-Louis hospital. Prof. Molina has been the Chair of the Clinical Trial Group at the French National Agency for AIDS Research (ANRS), where multicentre clinical trials are reviewed and implemented in France (2005-2018). He is now a member of the strategic committee of ANRS. Working with the ANRS, he has been the principal investigator of a number of clinical trials in HIV-infected patients. More recently, Prof. Molina has broadened his field of interest to the prevention of HIV infection with antiretrovirals and has led the ANRS IPERGAY PrEP trial in men who have sex with men in France and Canada. He is also the principal investigator of a new PrEP study (ANRS Prevenir) to assess the public health impact of PrEP in the Paris region to reduce the number of new HIV-infections and has conducted research in the field of sexually transmitted infections.
Yvonne Gilleece trained in Dublin and London, is a Consultant in HIV & Sexual Health at Brighton & Sussex University Hospitals NHS Trust and is an Honorary Senior Lecturer at Brighton & Sussex Medical School. She has a special interest in HIV & Women and is Chair of SWIFT, promoting research in women living with HIV and is Chair of the BHIVA Pregnancy Guidelines. She also specialises in HIV and Hepatitis Coinfection & Liver Dysfunction and HIV and Bone. She regularly presents research nationally and internationally.
Carine Van Lint is Professor at the University of Brussels (ULB, Belgium) and Research Director of the Belgian National Fund for Scientific Research (F.N.R.S.). She is author and co-author of more than 90 international publications in the field of retrovirology and molecular biology. After performing her PhD thesis at the National Institutes of Health (NIH, Bethesda, USA) and a post-doctoral fellowship at the Picower Institute in New-York, she joined the Faculty of Science of the University of Brussels (ULB) as the Director of the Laboratory of Molecular Virology. Her research aims at studying the molecular and epigenetic mechanisms regulating transcriptional latency and reactivation from latency in 3 retroviruses: HIV-1 and two oncogenic retroviruses HTLV-I (human T cell leukemia/lymphoma virus type 1) and BLV (Bovine Leukemia Virus). Regarding HIV-1, one of the major objective of her laboratory is to design, based on transcriptional mechanisms, novel strategies to reduce the pool of latent reservoirs to a level bearable by the host immune system.
Shema Tariq is a Postdoctoral Clinical Research Fellow at University College London (UCL) Institute for Global Health, and Honorary Consultant HIV Physician at Mortimer Market Centre, where she has develoFFped and leads a dedicated HIV menopause service. Her main area of interest is the reproductive and post-reproductive health of women living with HIV. Shema is trained in both epidemiology and medical anthropology and has particular expertise in mixed-methods public health research. Her academic experience includes doctoral research exploring women’s engagement with HIV care in the UK during pregnancy, and a Fulbright Scholarship to Columbia University (New York) to analyse cohort data on late HIV diagnosis in KwaZulu-Natal. She is Vice-Chair of the British HIV Association’s HIV and pregnancy Guidelines Writing Committee, Vice-Chair of SWIFT (a national knowledge network for research in HIV and women) and sits on the expert panel for the national audit of perinatal HIV infection. Shema is currently Chief Investigator of the PRIME Study, an NIHR-funded study investigating the impact of the menopause on the health and well-being of women living with HIV, and co-investigator on the forthcoming EPSRC-funded project INTUIT which will look at the use of patient-generated data in HIV.
This meeting is supported by educational grants from ViiV Healthcare, Gilead Sciences, Merck Sharp & Dohme and Janssen Sciences Ireland which have taken no role in designing the agenda or educational content of the meeting